Etoricoxib
- Generic Name
- Etoricoxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H15ClN2O2S
- CAS Number
- 202409-33-4
- Unique Ingredient Identifier
- WRX4NFY03R
- Background
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
- Indication
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
- Associated Conditions
- Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain
- Associated Therapies
- -
Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Anne Margarita Dyrhol Riise
- Target Recruit Count
- 39
- Registration Number
- NCT02503839
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Oslo University Hospital, Oslo, Norway
EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).
- Conditions
- Cyclooxygenase Two InhibitorsEtoricoxibPeriodontitisSuperoxide DismutaseSaliva
- Interventions
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Tatyasaheb Kore Dental College
- Target Recruit Count
- 40
- Registration Number
- NCT02149758
- Locations
- 🇮🇳
Tatyasaheb kore Dental College And Research Centre, Kolhapur, Maharashtra, India
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
- Conditions
- OsteoarthritisAnkylosing SpondylitisGoutArthritisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 79189
- Registration Number
- NCT01685424
Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 139
- Registration Number
- NCT01462370
A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01429168
Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Azienda Sanitaria Locale 4, Teramo
- Target Recruit Count
- 250
- Registration Number
- NCT01344720
- Locations
- 🇮🇹
Unità di riabilitazione neurofisiologica Istituto Scientifico di Riabilitazione di Montescano, Montescano (PV), Pavia, Italy
🇮🇹Dipartimento di Scienze della Salute Anestesia, Rianimazione e Terapia del dolore - Università degli Studi di L'Aquila Ospedale San Salvatore L'Aquila, L'Aquila, Italy
🇮🇹Clinica Anestesia e Rianimazione Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy
Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
- Conditions
- Spondylarthropathies; Spondylitis, Ankylosing
- Interventions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 21108
- Registration Number
- NCT01327638
Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01304069
- Locations
- 🇫🇮
Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland
Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching
- Conditions
- Color Changes During Tooth Formation
- Interventions
- Other: PlaceboDrug: Etoricoxib
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Eloisa Andrade de Paula
- Target Recruit Count
- 30
- Registration Number
- NCT01300780
- Locations
- 🇧🇷
Universidade Estadual de Ponta Grossa, Guarapuava, Paraná, Brazil
Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- X-pert Med GmbH
- Target Recruit Count
- 50
- Registration Number
- NCT01271348
- Locations
- 🇩🇪
X-pert Med GmbH, Jena, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.